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Summary Tumours of the head and neck were examined for gene amplification and expression of the
epidermal growth factor (EGF) receptor by Southern blot and Western blot analyses. The EGF receptor gene
was found to be amplified in four (19%) of 21 squamous cell carcinomas. The EGF receptor was
overexpressed in eight (53%) of 15 squamous cell carcinomas examined, including all four tumours showing
gene amplification. No amplification or overexpression of the EGF receptor gene was detected in any of nine
malignant or eight benign tumours of other types of the head and neck. The tumours showing amplification
and/or overexpression of the EGF receptor gene (8/15) were all identified histologically as well differentiated
squamous cell carcinomas, whereas none of the histologically less differentiated squamous cell carcinomas
(0/9) showed amplification and/or overexpression of the EGF receptor gene. Within our sample set, no
correlation was evident between amplification and/or overexpression and the clinical stage or tumour site.
Our results support the possible involvement of gene amplification and overexpression of the EGF receptor in
a subclass of squamous cell carcinomas of the head and neck.
Several oncogenes have been identified in human tumours
and there is accumulating evidence that oncogenes may be
involved in different stages of the multi-step carcinogenesis
process. For instance, ras oncogenes have been detected at
high incidence in various human tumours. The N-myc
oncogene has been found in a significant percentage of
human neuroblastomas and its incidence has been shown to
be well correlated with the clinical stage of these tumours
(Pelicci et al., 1984).
EGF is a polypeptide with potent mitogenic activity that
stimulates proliferation of a variety of cells through
interaction with its receptor. The EGF receptor is a trans-
membrane glycoprotein of Mr 170,000 on the surface of
many types of cells. From sequence analysis, the EGF
receptor gene is suggested to be the proto-oncogene of the
erbB oncogene (Yamamoto et al., 1983; Downward et al.,
1984). Therefore, qualitatively and/or quantitatively
abnormal expression of the EGF receptor gene may be
involved in some stage of carcinogenesis. High levels of EGF
receptor expression have been observed in some types of
tumours (Gullick et al., 1986; Berger et al., 1987; Ro et al.,
1988; Yasui et al., 1988), sometimes associated with
amplification of the EGF receptor gene.
There are only a few reports related to oncogenes involved
in tumours of the head and neck. Most tumours in these
regions are squamous cell carcinomas. Since A431 cells,
which were established from a squamous cell carcinoma,
express 10-50 times more EGF receptor than do most other
cell lines (Merlino et al., 1984), involvement of the EGF
receptor gene in tumours of the head and neck is of
particular interest. In fact, amplification of the EGF receptor
gene (Yamamoto et al., 1986) and increased EGF receptor
(Cowley et al., 1986) were observed in the case of a number
of cell lines derived from human squamous cell carcinomas.
In addition, Ozanne et al. (1986) quantitated overexpression
of EGF receptor in human squamous cell carcinomas from a
number of tissue sites, including 12 head and neck tumours.
In the present study, we have examined an additional 38
head and neck tumours, including 21 squamous cell
carcinomas, both for overexpression of the EGF receptor
and for gene amplification. We have further examined the
relation between these biochemical findings and both the
histological characteristics and the clinical features of the
tumours.
Materials and methods
Patients and tissues
In the present study, we examined tissues from 40 patients
treated in the Department of Otolaryngology, National
Medical Center Hospital, or the Department of
Otolaryngology, The Tokyo University Hospital. These
tissues consisted of 30 malignant tumours, eight benign
tumours and two specimens of normal squamous epithelium
(Table I). Of the malignant tumours, 21 were squamous cell
carcinomas, the detailed clinical and histological features of
which are shown in Table II. The tumour tissues were
obtained by biopsy from untreated patients or patients with
recurrent tumours, and were frozen and stored at -80°C
until analysis.
DNA isolation and Southern blot hybridisation
High molecular weight DNA was prepared from thin slices
of frozen tissues as described previously (Wigler et al., 1979).
The DNAs (104g) were cleaved with the restriction endo-
nuclease EcoRI, fractionated on the basis of size by electro-
phoresis in 1% agarose gel, denatured, neutralised and
Table I Histological classification of
tumours
Histology No.
Malignant tumour
Squamous cell carcinoma
Adenocarcinoma
Malignant lymphoma
Sarcoma
Malignant melanoma
Benign tumour
21
3
3
2
1
8
Normal squamous cell epithelium 2
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transferred to nitrocellulose filters as described (Southeri
1975). The filters were hybridised with a 32P-labelle
complementary DNA (cDNA) probe (specific activit'
2 x 108 c.p.m. per ,ug DNA) prepared by nick-translation c
the DNA insert from the EGF receptor cDNA clone pE
(Xu et al., 1984a) for 12h at 42°C. Then the filters wer
washed with 0.1 x standard saline citrate (SSC) containin
0.1% sodium dodecyl sulphate (SDS) for 30min and wit
2 x SSC containing 0.1% SDS at 60°C for 60min, afte
which they were exposed to X-ray film. Sequentiz
hybridisations of the filters were carried out after washin
them with hybridisation buffer at 70°C for 30min to remov
the previous probe. The filters were hybridised with the e
myc, Ki-ras, erbB-2, and yes oncogenes to confirm that equz
quantities of DNA were loaded on each lane. The intensit
of bands was quantitated by scanning the spots on the X-ra
film with a Shimazu Dual-Wavelength Flying-Spot Scanne
CS-9000. The amplification was evaluated by comparin
data on hybridisation with various oncogene probes an
photographs of the electrophorograms of DNA stained wit
ethidium bromide. High molecular weight DNA fror
placenta, which has a single copy of the EGF receptor gen
per cell, was used as a control.
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Figure 1 Amplification of EGF receptor gene in squamous cell
carcinomas. Lanes 1-3 and 5-8 contain DNAs (10pg) from
patients 19, 1, 6, 7, 17, 10 and 18, respectively. Lane 4 contains
DNA from placenta. Bars indicate the positions of materials of
9.4, 6.7, 4.4, 2.3 and 2.0kbp, respectively. Equivalent loading
was confirmed by hybridisation with myc, ras, erbB-2 and yes
oncogenes (data not shown).
n,
Id
1Y,
of
-7
re
ig
th
er
al
lg
ve
c-
al
ty
ty
er
19
Analysis of expression of the EGF receptor (Western blotting)
Protein was solubilised from thin slices of frozen tissues with
Tris-Cl buffer, pH 6.8, containing 2.3% SDS and 5% 2-
mercaptoethanol at 100°C for 15min, and the supernatant
was used as the lysate. Western blotting was performed as
described (Towbin et al., 1979). Briefly, lysates equivalent to
50pg of protein were loaded onto 7.5% SDS-polyacrylamide
gels. After electrophoresis, the fractionated samples were
electroblotted onto nitrocellulose filters. The filters were
incubated with anti-EGF receptor antibody, which was a gift
from Dr Ira H. Pastan (NCI, USA). Staining was done with
a Proto Blot Immunoscreening kit (Promega Biotec). Lysates
of placenta and A431 cells were used as positive controls.
Results
d High molecular weight DNAs from tumour tissues were ih cleaved with EcoRI and subjected to Southern blot
m hybridisation. The pattern of multiple bands of the EGF
e receptor gene was similar to that characterised previously
(Yamamoto et al., 1986). Examples of autoradiograms of the
squamous cell carcinomas are shown in Figure 1 and data
on the 21 squamous cell carcinomas examined are
summarised in Table II. The EGF receptor gene was
amplified 5.4 and 2.3-fold in two squamous cell carcinomas
from the larynx (cases 3 and 6), 8.8-fold in one from the
tongue (case 17) and 8.0-fold in one from the ear (case 18).
These tumours were all classified histologically as well
differentiated squamous cell carcinomas, but there was no
correlation between amplification of the gene and clinical
features such as the site or stage of the tumours. No
amplification of the EGF receptor gene was observed in any
of the other malignant or benign tumours examined. Thus,
the incidence of amplification of the EGF receptor gene was
higher in well differentiated squamous cell carcinomas (4/12)
than in other types of squamous cell carcinomas (0/9) or
other tumours (0/17).
The EGF receptor gene shows restriction fragment length
polymorphism (RFLP) of a fragment of about 4.5kbp,
which was generated by cleaving the DNA with the
restriction endonuclease EcoRI (K. Kawashima & S.
Nishimura, personal communication). We detected this
RFLP in specimens from two pleomorphic adenomas, one
malignant melanoma and one normal nasopharynx
epithelium (Figure 2). In these cases, the EGF receptor gene
was not amplified.
Table II Gene amplification and expression of EGF receptor in squamous cell carcinomas
Site
Larynx
Larynx
Larynx
Larynx
Larynx
Larynx
Larynx
Sinuses
Sinuses
Sinuses
Sinuses
Hypopharynx
Hypopharynx
Hypopharynx
Tongue
Tongue
Tongue
Ear
Ear
Nasopharynx
Floor of mouth
TNMa Stagea
T3NOMO
T3N2aMO
T3N2cMO
T2N2MO
T3N1MO
TIbNOMO
T2NOMO
T4NOMO
T2NOMO
T3NOMO
T4NOMO
T3N2aMO
T4N2MI
T2NlMO
T3NOMO
T2NOMO
T2NOMO
III
IV
IV
IV
III
I
II
IV
II
IV
IV
IV
IV
II
IV
II
II
T3N2MO IV
T3N3MO IV
Differentiation
Moderately
Poorly
Well
Moderately
Moderately
Well
Poorly
Well
Well
Well
Well
Well
Moderately
Poorly
Well
Well
Well
Well
Well
Poorly
Moderately
Amplification Expressionb
1.1 x
1.1 x
5.4x
0.9x
1.1 x
2.3x
0.8x
1.5x
1.6x
1.6x
1.1 x
1.1 x
1.1 x
1.1 x
1.3 x
0.9x
8.8x
8.0x
1.1 x
1.0 x
0.8x
NDd
1+
ND
ND
1+
ND
2+
1+
1+
ND
+
ND
+
1+
2+
2i+
bThe symbols are
Patient
no. age/sex
1. 73/M
2. 72/M
3. 63/M
4. 57/M
5. 71/M
6. 78/M
7. 77/M
8. 80/F(R)C
9. 75/M
10. 62/M
11. 68/F(R)
12. 63/M
13. 84/F
14. 61/F
15. 62/M
16. 59/M(R)
17. 47/F
18. 74/F(R)
19. 90/M(R)
20. 62/F(R)
21. 39/M
aStaged according to TNM classification of malignant tumours (UICC, 1987);
defined in the text; C(R), recurrent tumour; dND, not determined.EGF RECEPTOR IN SQUAMOUS CELL CARCINOMA 561
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Figure 2 RFLP of the EGF receptor gene. Lanes 2, 3 and 8
contain abnormal 4.5 kbp (arrowhead). These DNAs were
obtained from two pleomorphic adenomas and normal naso-
pharynx epithelium, respectively. Bars indicate the position of
DNAs of 9.4, 6.7, 4.4, 2.3 and 2.0kbp, respectively.
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Figure 3 Expression of EGF receptor in squamous cell carcino-
mas. Lysates (50jug) from tissues were analysed by Western
blotting with an antibody against the EGF receptor. Lanes 1-5
are lysates of tissues *from patients 1, 17, 12, 18 and 13,
respectively. Lanes 6 and 7 are lysates of normal squamous cell
epithelium and placenta. Arrowheads indicate the position of
material of Mr 170,000.
For determination of whether the EGF receptor was
overexpressed, 15 of 21 squamous cell carcinomas were
subjected to Western blot analysis with anti-EGF receptor
antibody (Figure 3). The expression was graded as follows:
lysate staining more than the placenta, 2+; lysate staining
more than normal squamous epithelium, 1 +; lysate staining
the same or less than normal squamous epithelium, +; no
detectable staining, -; ND, not determined due to lack of
material. Overexpression of the EGF receptor was observed
in eight cases of squamous cell carcinoma (Table II). This
overexpression was seen in all cases showing EGF receptor
gene amplification and so was thought to result from gene
amplification. But four of the eight cases of overexpression
did not show gene amplification, All eight cases were of
tumours classified histologically as well differentiated
squamous cell carcinomas. In other words, overexpression of
the EGF receptor was observed in eight (73%) of 11 well
differentiated squamous cell carcinomas examined but in
none (0/4) of the moderately or poorly differentiated
squamous cell carcinomas. This difference is statistically
significant (P<0.05, Fisher's exact test).
Discussion
There are few published studies of oncogene amplification/
expression in squamous cell carcinomas of the head and
neck. Spandidos et al. (1985) examined 14 specimens of
squamous cell carcinoma of the head and neck and found
that in most cases the expression of the ras and myc
oncogenes was elevated but that these genes were not
amplified. In another paper (Field et al., 1986), no
correlation was found between elevated expression of these
genes and clinical features other than for a significant
difference between myc expression in early and in advanced
stages of tumour development. Ozanne et al. (1986) indicated
that overexpression of the EGF receptor was a common
property of squamous cell carcinomas, including tumours of
the head and neck, and that amplification of the EGF
receptor gene was found frequently. No mention was made
of any correlation between these findings and the state of
differentiation of the tumours or clinical features.
In the present study, we examined 40 specimens from
patients with tumours of the head and neck for gene
amplification and expression of the EGF receptor. Gene
amplification was analysed by Southern blot hybridisation
and results showed that the EGF receptor gene was
amplified about 8.8, 8.0, 5.4 and 2.3-fold, respectively, in
four of 21 squamous cell carcinomas. This level of
amplification in the tumour specimens was less than that in
the cell lines reported previously (Yamamoto et al., 1986).
However, unlike cell lines, human solid tumours are hetero-
geneous and contain other tissues and stromal elements, so
the measured increases will understate the actual
amplification in the tumour cells. No malignant or benign
tumours other than squamous cell carcinomas showed
amplification of the EGF receptor gene. Moreover, in the
squamous cell carcinomas tested, the c-myc, Ki-ras, erbB-2
and yes oncogenes were not amplified (data not shown).
These results suggest that amplification of the EGF receptor
gene may be one of the specific gene abnormalities of
squamous cell carcinomas of the head and neck.
Recently the level of EGF receptor expression, detected by
Western blotting, was reported to be correlated with the
immunohistochemical reactivity of the EGF receptor (Yasui
et al., 1988). Moreover, the EGF receptor was shown to be
overexpressed on cytoplasmic membranes (Ro et al:, 1988).
In general, Western blotting is more quantitative than
immunohistochemical analysis. Therefore, to determine
whether amplification of the EGF receptor gene resulted in
overexpression of the receptor, we examined lysates of the
tumour tissues by Western blotting with antibody against the
EGF receptor. Results showed a good correlation between
gene amplification and overexpression of the receptor, sug-
gesting that gene amplification leads to overexpression of the
receptor, in agreement with the previous report (Ozanne et
al., 1986). However, we also observed overexpression of the
receptor in four other squamous cell carcinomas in which no
amplification of the gene was detected. This finding indicates
that gene amplification is not the only mechanism by which
the level of the EGF receptor can be increased, as stated
previously (Xu et al., 1984b).
Of special interest in the study is the observation that all
tumours showing amplification and/or overexpression of the
EGF receptor were identified histologically as well
differentiated squamous cell carcinomas. These results
suggested that overexpression of the EGF receptor may be
related to differentiation as compared with myc expression
(Field et al., 1986), which is stage-related in squamous cell
carcinomas of the head and neck. This finding is similar to a
report (Yokota et al., 1988) that amplification of erbB-2 is
relatively high in the well differentiated type of gastric
carcinoma.
Recently, a correlation was observed between invasiveness
of human bladder tumours and overexpression of EGF
receptor (Neal et al., 1985), suggesting that examination of
this receptor is useful for predicting the prognosis of
tumours. There is also a report that advanced gastric
carcinomas showed a higher level of expression of the EGF
receptor than early gastric carcinomas, but that this
correlation was not found in colon carcinomas (Yasui et
al., 1988). In our series, amplification or overexpression was
not related to the stage or site of the tumours. Therefore, the
clinical features of a tumour can be explained in terms of
expression of a particular oncogene only in certain types of
tumours.562 J. ISHITOYA et al.
Southern blot analysis revealed RFLP of the EGF
receptor gene in four of the cases tested. This RFLP was
detected as an abnormal band of 4.5kbp. Kawashima and
Nishimura (personal communication) suggested that this
RFLP was closely related to gastric carcinoma and may be
an indicator for prediction of the appearance of gastric
carcinoma. In contrast, RFLP was not detected in any of the
patients with squamous cell carcipioma examined in our
present study. These results suggest that RFLP of the EGF
receptor gene has no influence on development of squamous
cell carcinoma of head and neck. Similarly, no correlation
between RFLP of the Ha-ras oncogene and colon adeno-
carcinoma was found (Nelli et al.; 1987). Interestingly, we
observed RFLP in each of the two patients with pleo-
morphic adenoma. Larger numbers of patients will need to
be examined to determine whether this association is
significant.
In the present study, we demonstrated high incidences of
amplification and/or overexpression of the EGF receptor
gene in well differentiated squamous cell carcinomas of the
head and neck. However, our results did not indicate the
clinical significance of overexpression of the EGF receptor.
Further studies are needed to determine whether gene
amplification and/or overexpression of the EGF receptor is
related to the development or prognosis of these squamous
cell carcinomas.
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